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The purpose ofNational Toxicology Program
(NTP) toxicology/carcinogenicity studies is to
identify toxic/carcinogenic effects resulting
from exposure to a particular chemical or
agent and to characterize dose-response rela-
tionships. In support of the toxicology/car-
cinogenicitystudies, toxicokinetic (TK) studies
are conducted to characterize the absorption,
distribution, metabolism, and elimination
(ADME) ofxenobiotic materials and to quan-
tify the influence ofexposure on those proper-
ties. Toxicokineticstudies areproposed to
* help in the design (e.g., dose selection,
route ofexposure, etc.) ofmeaningful and
useful toxicology studies;
* aid in the interpretation oftoxicology stud-
ies by increasing our understanding ofrela-
tionships between exposure, time-depen-
dent target organ dosimetry, and adverse
effects; and
* define the parameters ofdose, distribution,
metabolism, and elimination that can be
used in human risk assessment.
Toxicokinetic studies also investigate the
effects of sex, species, and age on ADME.
Data collected during a toxicokinetic study
focus on timeprofiles ofparent chemical and
metabolite concentrations in plasma and
other tissues and can include rates ofchemi-
cal absorption, metabolism, and excretion,
chemical related changes in blood chemistry,
bioavailability, protein binding, and deple-
tion ofcofactors.
Ultimately, the data gathered during
toxicology/carcinogenicity studies are used
to estimate the risk to human health from
exposure to a chemical. Characterization of
relationships between toxic/carcinogenic
endpoints and target organ dosimetry aid in
the estimation ofhuman risk. A description
ofa study design well-suited to the support
of human risk assessment follows. This
comprehensive design aims to collect the
data necessary to develop physiologically
based pharmacokinetic (PBPK) models
incorporating some degree of anatomical
realism and including all relevant biochem-
ical and physiological processes. Prior to the
determination of toxicological effects, it is
impossible to propose a TK study design
that is sufficient for all chemicals. The
design proposed below contains elements
believed to be necessary for the construc-
tion of PBPK models. The relative impor-
tance of some measurements may change
depending on the compound understudy.
Two of the most difficult but critical
problems in risk assessment are defining
equivalent human dose and delineating the
dose-response curve in the low-dose region
(i.e., below the range of the experimental
data). These problems motivate the recom-
mendations to collect data to support the
development and validation of PBPK
models. If the only information available
to the risk assessor is the applied or extemal
dose, the estimated human equivalency
dose will be based on several assumptions,
such as equivalent absorption in laboratory
animals and humans. However, uncertain-
ties may exist in the predicted low-dose
effects in humans if all of the doses that
caused the adverse effect in the animal
model occurred above the metabolic satura-
tion exposure, if the chemical is absorbed
differently in animals than in humans, or if
the chemical is metabolized differently
(qualitatively or quantitatively) between
species. An objective of toxicokinetic stud-
ies is to improve our understanding of the
relationship between external exposure and
the tissue level ofthe toxic agent at the tar-
get site. By increasing our understanding of
the relationships between target organ
dosimetry and adverse effects, confidence in
low-dose extrapolations ofrisk to humans is
increased. Thus, knowledge ofinternal dose
and factors that influence absorption, distri-
bution, metabolism, and elimination in
experimental animals and humans provide a
greater scientific rationale for estimating
low-dose risk than do estimates that are
based solely on external exposure.
Exposure- and time-dependent changes in
target tissue concentrations of a parent
compound and metabolites (especially ifthe
adverse affects ofexposure are due to partic-
ular metabolites) provide an even stronger
scientific foundation for estimating equiva-
lent human dose in various risk assessment
models. Toxicokinetic/pharmacokinetic
models provide the basis for more accurate
low-dose extrapolations to humans. PBPK
models can be adapted to different routes of
exposure and dosage regimens and can
accommodate factors that contribute to
interindividual variabilities. Thus, the mod-
eler can also provide valuable information
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relevant to the distribution of risk in
exposed populations. The combination of
dosimetry models with mechanistic data
(e.g., mutagenicity, altered gene expres-
sion) can lead to more realistic biological
models that would be useful in predicting
site-specific dose responses and assessing
human risk.
For most of the chemicals studied by
the NTP, the mechanisms of toxicity or
carcinogenicity are not known. In the
absence ofknowledge regarding the mecha-
nism of action of a chemical, it is impor-
tant to measure the effects of dose on
chemical fate in test animals. To maximize
the sensitivity ofNTP bioassays, chemicals
are often studied at doses that are far in
excess of those that humans are likely to
encounter. For some chemicals the effect of
the dose on the test species is determined
by measuring the plasma levels of the par-
ent compound and metabolites over the
dose range of interest. For other chemicals
the critical toxic action may occur in the
stomach, gastrointestinal tract, or liver
prior to entering the systemic circulation.
Even when the amount of parent com-
pound absorbed into the systemic circula-
tion is proportional to the dose adminis-
tered, the metabolites that may actually
account for toxicity associated with expo-
sure to the parent compound may not be
formed in or cleared from the target tissues
in a manner proportional to dose. These
parameters can be determined only
through detailed studies ofthe dose-depen-
dent metabolism and disposition of the
chemical in question. For chemicals with
low toxicity or which were not carcino-
genic under the conditions ofthe bioassay,
there may be little need for studies support-
ing the development of mechanistic mod-
els. However, negative toxicology studies
and adequate disposition studies may pro-
vide valuable information on positive stud-
ies of structurally related chemicals. If the
metabolic processes associated with a
chemical differ between species, detailed
modeling and comprehensive studies may
be necessary. Chemicals of moderate or
unknown toxicity (and/or equivocal car-
cinogenicity) that are important to public
health may warrant comprehensive studies
aimed at identifying the mechanisms of
toxicity/carcinogenicity and associated
pharmacokinetic parameters.
In the next section, we describe a gener-
al approach for a comprehensive toxicoki-
netic study and make suggestions ofareas in
which the design could be tailored for a
specific chemical. Clewell and Andersen (1)
describe the utility and advantages ofusing
PBPK models in interpreting the results of
toxicology experiments and in assessing
human risk. In the last section, we describe
a minimal approach that would be useful
for the design of toxicology/carcinogenicity
studies. It should be emphasized that the
two approaches represent the extreme ends
of a continuum of designs. Most studies
will follow protocols that fall somewhere
between these extremes. Study designers are
free to eliminate elements from the compre-
hensive design that are inappropriate or
unattainable for the chemical of interest or
to add features to the minimal approach to
answer specific questions of interest. The
chemistry and toxicity of a specific com-
pound may change the nature of the study
conducted. For example, measurement of
parent chemical and metabolite levels in the
bile via bile duct cannulation may be useful
for chemicals known or thought to undergo
significant enterohepatic recirculation.
Otherwise, the efforts and expense involved
in bile duct cannulation may be unwarrant-
ed. Customization of study design should
always be considered.
A Comprehensive Toxicokinetic
Study Design
To facilitate an understanding between
exposure and tissue dosimetry, a toxicoki-
netic study should aim to answer the fol-
lowing five questions for the chemical
under study: 1) Is the chemical absorbed
(rate and degree)? 2) Where are the chemi-
cal and/or metabolites distributed in the
body? 3) How is the chemical metabolized
(site and rate ofmetabolism and identifica-
tion ofmetabolites)? 4) What are the elimi-
nation rate and elimination route(s) of the
chemical and possibly its metabolite(s)? 5)
What is the effect of dose on absorption,
distribution, metabolism, and elimination?
The answers to these questions are help-
ful in the construction ofpharmacokinetic/
toxicokinetic models, design of toxicology
studies, and interpretation of animal dose
response. Conversely, an existing properly
constructed pharmacokinetic/toxicokinetic
model should be able to predict answers to
these questions. The accuracy ofprediction
will depend on the degree of physiological
and biochemical fidelity captured by the
model. If the ultimate goal of the animal
study is to estimate risks to human health
from chemical exposure, higher quality and
more reliable risk estimates can be made
from mechanistic models such as well-con-
structed and validated PBPK models. Such
models would certainly require the use of
human parameter values obtained from
human tissue samples and volunteers. This
section covers a proposed study design to
support the development ofa PBPK model.
The reader should keep in mind that this
study design is proposed without regard to
a specific chemical. There will no doubt be
chemicals for which this proposed design
will be inappropriate, inadequate, or
impractical. For those chemicals, the fol-
lowing approach should be used as a start-
ing point and modified to address the par-
ticular constraints and needs of working
with those chemicals.
Animals. The same strain and species
used in the toxicology studies should be
used in the TK studies. Initial studies may
involve one sex of each species (e.g., male
rats and mice). The use ofmore than a sin-
gle species of test animal is relevant to the
question of expected differences in bio-
chemical processes between test animals
and humans. If a sex difference in toxic
response is found, then TK studies will be
necessary in the second sex. Young healthy
adults (10-12 weeks of age, matched for
body weight) should be used, except for
studies examining the effect of age on the
ADME of a chemical. Sufficient animals
should be included in the TK study design
to guarantee a minimum ofthree data sam-
ples per time point ofanalysis.
Chemical. Radiolabeled chemicals
should be used if available or if their syn-
thesis is economically and technically feasi-
ble. Radiolabeled chemicals have the
advantage that the total amount of parent
compound plus metabolites in a tissue at
the time ofsampling are easily and quickly
measured. As noted below, analyses of tis-
sue samples should distinguish the parent
compound from its metabolites. Ifit is not
possible to synthesize the radiolabeled par-
ent compound, unlabeled material may be
used to determine toxicokinetic properties
of the chemical if a sensitive analytical
method is available. Unlabeled material
may also be used if an objective of the
study is to evaluate ADME in the same
animals that are on study for toxicological
evaluations.
Storage and disposal ofcarcasses, tissue
samples, excreta, and excess radiolabeled
chemicals will always be a concern and
result in greater expense compared to the
use of unlabeled chemicals. It is probably
impractical to conduct a long-term expo-
sure study using radiolabeled chemicals,
especially in dosed feed or drinking water
exposures. Thus it is important that analyt-
ical methods of sufficient sensitivity be
developed for the parent chemical and
metabolites of interest so that the use of
radiolabeled chemicals in later stages of
studies can be minimized or eliminated.
Analyses. For radiolabeled chemicals,
excreta and tissue samples should be
assayed for total radioactivity. The samples
should then be subjected to a procedure
that separates and quantitates the amount
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of radioactivity in the parent compound
and metabolites (e.g., high pressure liquid
chromatography, gas chromatography).
Positive identifications should be made for
major metabolites and those that account
for >10% of the absorbed dose. If the
mechanism of toxicity/carcinogenicity is
known or thought to be due to the produc-
tion of a specific metabolite, then if possi-
ble, concentrations of that metabolite
should be measured at least in the target
tissue or organ, blood, and the site of
metabolite production. This information is
of fundamental importance to the transla-
tion ofexternal dose to toxic effect. Other
metabolites may need to be identified
under some circumstances.
Route ofexposure. The same route in
the toxicology study and/or the most com-
mon route of human exposure should be
used, plus the intravenous (iv) route, for
estimation of absorption. If feed or drink-
ing water will be the exposure route in the
toxicology study, gavage exposure should
also be included to estimate the absorption
parameter(s). Separate studies may be need-
ed to characterize the effect ofvehicle, dose
rate, and vehicle volume on absorption and
bioavailability ofthe parent compound.
Dose levels. The same doses used or
anticipated in the toxicology studies should
be used. A minimum of three doses is rec-
ommended. IfTK studies are conducted in
advance oftoxicology studies on the chemi-
cal, then the doses should approximate 0.1
median lethal dose (LD50), 0.01 LD50, and
0.001 LD 0 Three dose levels may be suffi-
cient to demonstrate dose proportionality;
however, additional doses, both higher and
lower than those mentioned, would provide
a better characterization ofthe linear kinetic
range and a more accurate estimation ofthe
dose level at which the onset of nonlinear
kinetics occurs.
Samples. For the iv route of exposure,
samples should be taken for each ofthe tis-
sues: blood (or plasma), fat, muscle, liver,
and kidney. If a target organ or tissue for
the chemical under study is known or antic-
ipated and is not included in the above list,
it should be sampled also. Sampling times
will depend on the rate at which the chemi-
cal is eliminated or metabolized and on the
sensitivity of the analytical method. For an
iv administration, samples should be col-
lected at several (8-12) time points. For
example, if the plasma concentration of a
chemical after a specified dose reaches the
limit of detection of the analytical method
at approximately 24 hr, samples might be
collected at 5, 10, 20, 40, and 60 min and
2, 4, 6, 8, and 24 hr after dosing. Excreta
should be collected for analysis at several
time points over this same interval. For
volatile chemicals or volatile metabolites,
expired air should also be collected.
For many chemicals administered via
inhalation, the plasma levels of chemical
drop rapidly once an animal is removed
from exposure. Blood samples can be taken
during exposure ifthe exposure is performed
in a nose-only exposure system. Rats can be
sampled from the tail vein, implanted jugu-
lar cannula, or by cardiac puncture. Mice
are limited to sampling by cardiac puncture.
Jugular cannulated animals should be
allowed sufficient time to recover from
surgeryand anesthesia before exposure.
For other non-iv routes of exposure,
samples ofthe same tissues listed for the iv
route should be taken (plus skin ifthe non-
iv route is dermal). To characterize the
extent ofabsorption and routes ofelimina-
tion, additional groups of dosed animals
should be included for collection and
analyses of excreta, carcass, and (if appro-
priate) expired air. Animals should be fed
the night before dosing. The samples
should be taken at several time points
(10-12) sufficient to characterize the
chemical concentration in plasma or other
tissues versus time profiles. Sampling inter-
val and times will depend on the rate of
absorption and clearance of the chemical.
To characterize the absorption rate and
maximum concentration (Cmax), samples
are needed at three distinct times prior to
the time at which the peak blood concen-
tration is reached. A pilot study may be
needed to help select the appropriate sam-
pling times for this phase of the experi-
ment. Special care must be taken to not
disturb the feeding habits ofthe remaining
animals on test during the collection of
night-time blood samples.
Partition coefflicients. For the develop-
ment of PBPK models, tissue:blood parti-
tion coefficients should be obtained for the
parent compound and toxic metabolites in
fat, muscle, liver, kidney, and additional
major metabolizing tissues, target organs,
and storage depots (if not included among
the specifically listed tissues). Anomalies
between tissue hydrophobicity and parti-
tioning characteristics can be evidence of
specific binding in tissues. For volatile
compounds, the vial head-space technique
(2,3) is often used to measure partition
coefficients, whereas nonvolatile com-
pounds may be more amenable to the tech-
nique ofJepson et al. (4). For nonvolatile
compounds that are cleared slowly,
tissue:blood partition ratios may be mea-
sured at steady state after repeated exposure
to a chemical.
Enzymology. The biochemical realism
of the PBPK model depends on an under-
standing and quantitative characterization
of the processes that convert a xenobiotic
to possibly one or more metabolites and
the processes that detoxify the parent
chemical and metabolites. It may be that
the toxic/carcinogenic agent is actually a
short-lived reactive intermediate that could
be difficult to measure in tissue samples. It
may be possible to obtain kinetic constants
for the production and degradation ofreac-
tive intermediates in vitro. Although an in
vitro study of the parent compound and a
metabolite may ignore complicating inter-
actions present in vivo, it presents an
opportunity to measure production and
detoxification rates needed for initial con-
struction of the model. The appropriate-
ness of this simplification of the biochem-
istry will be revealed during validation of
the model. The range of substrate concen-
trations tested in vitro should include the
range of concentrations expected in vivo,
provided sufficiently sensitive analytical
techniques are available. High substrate
concentrations should also be tested in
vitro to determine maximal rate (V'ax).
The PBPK model may need to include the
kinetics of cofactor changes (e.g., glu-
tathione, reduced nicotinamide adenine
dinucleotide, reduced nicotinamide ade-
nine dinucleotide phosphate) or competi-
tive binding between metabolites and/or
parent compound. Thus, the kinetics of
these changes should also be measured in
vitro. Use ofhuman tissue samples provides
an opportunity to compare metabolic
activities between laboratory animals and
humans. However, one should also be cau-
tious in making quantitative comparisons
because of the potential variability in the
quality ofnormal human tissue.
Model validation. The output of the
PBPK model should be compared against
experimental data that were not used to
estimate parameters for the model. For
example, model predictions could be com-
pared against an experiment in the same
species as that used to construct the model,
but using a different route of exposure,
dose level, or dose frequency. Comparison
between model predictions and experimen-
tal data in a species different from that used
to construct the model is also a method of
validation of the model structure. This
comparison will require model parameter
values for the second species. Accurate pre-
dictions ofcofactor changes can be used as
evidence of model validation. If practical
and ethical, human tissue or human volun-
teer studies can be used to determine the
validity of the PBPK model before it is
considered to besuitable forriskassessment. If
the agreement between the model output and
experimental data is not reasonable, the new
data should be used as a basis for improv-
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ing parameter estimates or changing the
form of the model. The output of the
improved model would then be compared
against yet another set of experimental
data. Model construction and validation
are iterative processes.
Multiple dosing. Single-dose experi-
ments are adequate except if changes in
metabolic enzyme levels are anticipated
(e.g., induction, suicide inhibition) or if
the chemical has a long half-life. In these
cases, 5 days to 2 weeks of dosing at the
same frequency as in the toxicology study
may be needed. If enzymatic changes are
important in the biotransformation of the
parent compound or its toxic metabolites,
the toxicity studies should include mea-
surements of the time-dependent changes
in these activities as a function ofdose.
Effects ofage. Ifmultiple dosing studies
provide the same parameter values as sin-
gle-dose studies, the effect of age on the
ADME ofthe chemical can be evaluated in
naive animals of different ages (e.g., 3, 6,
12, and 18 months). The PBPK model
parameters can be adjusted for the physiol-
ogy of aged animals (increased body
weight, increased percentage of body fat,
etc.). Predictions of the PBPK model
should be validated against experimental
data collected in aged animals. This may
reduce or eliminate the need to expose ani-
mals to a xenobiotic for extended periods
(e.g., more than 2 weeks) or it may justify
the need for a chronic exposure TKstudy.
AMinimalToxicokinetic Study
Design
In the previous section, we described a
study protocol design that could be used in
the development ofa PBPK model. It is at
one end of the spectrum of possible study
designs; at the opposite end is a minimal
study protocol. Toxicologists are not com-
pelled to make a choice between the two
extremes of protocol design. The minimal
protocol is a subset of the ideal protocol
and does not require the use ofradiolabeled
compound. This study design is likely to
answer only questions 1), 4), and 5) from
the list presented at the beginning of the
previous section and would greatly help in
the design and interpretation ofthe animal
toxicity studies. However, the inclusion of
some components of the comprehensive
protocol in the minimal protocol (e.g., sam-
pling excreta in addition to blood or mea-
suring partition coefficients) would further
improve the utility ofthe latter protocol in
interpreting the results ofa toxicology study
and in risk assessment. Both study designs
share the following common features.
Animals. The same strain and species as
in the toxicology studies should be used in
the TK studies. Initial studies may involve
one sex of one species (e.g., male rats).
Young healthy adults (10-12 weeks ofage,
matched for body weight) should be used,
except for studies examining the effect of
age on the ADME ofa chemical. Sufficient
animals should be included in the TKstudy
design to guarantee a minimum of three
datasamples per time point ofanalysis.
Chemical Radiolabeled chemical is not
required although it can be used ifavailable.
Route ofexposure. The same route in
the toxicology study or the most common
route of human exposure should be used,
in addition to the iv route for estimation of
absorption.
Dose levels. The same doses used or
anticipated in the toxicity studies should be
used. A minimum of three doses is recom-
mended. If TK studies are conducted in
advance oftoxicology studies on the chemi-
cal, the doses should approximate 0.1 LD50,
0.01 LD50, and 0.001 LD50. Three dose
levels may be sufficient to demonstrate dose
proportionality; however, additional doses
may be needed to more accurately estimate
where nonlinear kinetics occur.
Sampks. For an iv administration, sam-
ples should be collected at several (8-12)
time points. For example, if the plasma
concentration of a chemical after a speci-
fied dose reaches the limit of detection of
the analytical method at approximately 24
hr, samples might be collected at 5, 10, 20,
40, and 60 min and 2, 4, 6, 8, and 24 hr
after dosing. Rats can be sampled from the
tail vein, implanted jugular cannula, or by
cardiac puncture. Mice are limited to car-
diac puncture. If bile duct cannulation is
performed, animals should be protected
from dehydration. After a steady bile flow
is established, bile should be collected at
intervals separated by at least 30 min.
For non-iv routes of exposure, blood
samples (plasma or serum) should be col-
lected at several time points (10-12) suffi-
cient to characterize the chemical concen-
tration in plasma or other tissues versus
time profiles. Sampling interval and times
will depend on the rate of absorption and
clearance ofthe chemical.
Analyses. Blood/plasma samples should
be assayed for the administered compound.
For some chemicals (e.g., esters that are
rapidlyhydrolyzed), a major metabolite must
be measured insteadofthe parent chemical.
This design is similar to several proto-
cols already in use at the National Institute
of Environmental Health Sciences. The
minimal design almost completely ignores
the issue of metabolism and identification
of the toxic agent (if presumed different
than the parent chemical). This design is
purposely modest in scale. In most cases,
parameters obtained from disposition or
toxicokinetic studies in a single sex ofa sin-
gle species provide some indication of the
processes involved. If differences in LD50
or health effects between species or sexes
are known, it may be necessary to include
animals of more than one species or of
both sexes. In general, a chemical that is
readily absorbed by the male rat will be
readily absorbed by the female and by mice
and by humans, though the rates will not
be identical. Additional apriori knowledge
about a chemical could further change this
proposed design. For instance, study of a
chemical known to undergo significant
enterohepatic recirculation may call for the
use ofbile duct-cannulated animals.
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